We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Pembrolizumab, in combination with carboplatin and either paclitaxel or nanoparticle albumin-bound paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).
Therapeutic area
Oncology